Jim Simons Anavex Life Sciences Corp. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Renaissance Technologies LLC holds 243,800 shares of AVXL stock, worth $1.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

243,800

Previous 466,437 47.73%

Holding current value

$1.82 Million

Previous $1.97 Million 29.67%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$4.11 - $7.04 $915,038 - $1.57 Million	-222,637 Reduced 47.73%	243,800 $1.38 Million
Q2 2024 Aug 09, 2024	BUY	$3.39 - $5.02 $1.31 Million - $1.94 Million	386,537 Added 483.78%	466,437 $1.97 Million
Q1 2024 May 13, 2024	BUY	$4.55 - $6.75 $363,545 - $539,325	79,900 New	79,900 $407,000
Q3 2022 Nov 14, 2022	BUY	$8.9 - $12.86 $82,770 - $119,598	9,300 Added 2.6%	367,100 $3.79 Million
Q2 2022 Aug 12, 2022	BUY	$7.31 - $12.84 $2.62 Million - $4.59 Million	357,800 New	357,800 $3.58 Million
Q1 2021 May 13, 2021	SELL	$5.17 - $16.13 $326,227 - $1.02 Million	-63,100 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$4.01 - $7.58 $253,031 - $478,298	63,100 New	63,100 $341,000
Q2 2020 Aug 13, 2020	SELL	$2.62 - $5.2 $1.07 Million - $2.12 Million	-407,400 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$2.38 - $5.81 $775,544 - $1.89 Million	325,859 Added 399.63%	407,400 $1.28 Million
Q4 2019 Feb 13, 2020	BUY	$2.31 - $3.14 $188,359 - $256,038	81,541 New	81,541 $211,000
Q1 2019 May 14, 2019	SELL	$1.68 - $3.42 $30,423 - $61,932	-18,109 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$1.25 - $2.75 $22,636 - $49,799	18,109 New	18,109 $28,000

Others Institutions Holding AVXL

# of Institutions

154

Shares Held

27.3M

Call Options Held

515K

Put Options Held

838K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $581M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account